Last 7 days
-1.9%
Last 30 days
-11.0%
Last 90 days
-4.5%
Trailing 12 Months
-2.2%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-08-30 | Pettiti Gianluca | acquired | 761,970 | 253 | 3,000 | executive vice president |
2023-08-30 | Pettiti Gianluca | sold | -1,673,310 | 557 | -3,000 | executive vice president |
2023-08-28 | Williamson Stephen | sold (taxes) | -157,633 | 545 | -289 | sr. vp and cfo |
2023-08-28 | Holmes Joseph R. | sold (taxes) | -6,721 | 545 | -12.328 | vp & chief accounting officer |
2023-08-28 | CASPER MARC N | sold (taxes) | -509,274 | 545 | -934 | chairman & ceo |
2023-08-28 | Boxer Michael A | sold (taxes) | -56,675 | 545 | -103 | svp and general counsel |
2023-08-28 | Lagarde Michel | sold (taxes) | -190,846 | 545 | -350 | executive vice president & coo |
2023-08-28 | Britt Lisa P. | sold (taxes) | -60,891 | 545 | -111 | sr. vp and chief hr officer |
2023-08-28 | Pettiti Gianluca | sold (taxes) | -148,671 | 545 | -272 | executive vice president |
2023-08-25 | Pettiti Gianluca | sold (taxes) | -204,250 | 541 | -377 | executive vice president |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-09-26 | BROOKFIELD Corp /ON/ | reduced | -31.58 | -389,021 | 632,883 | -% |
2023-09-26 | DecisionPoint Financial, LLC | sold off | -100 | -11,528 | - | -% |
2023-09-26 | M Holdings Securities, Inc. | sold off | -100 | -549,000 | - | -% |
2023-09-21 | Jefferies Group LLC | added | 23.6 | 3,292,640 | 24,694,100 | 0.21% |
2023-09-21 | Baystate Wealth Management LLC | added | 214 | 108,668 | 167,742 | 0.01% |
2023-09-21 | Halpern Financial, Inc. | new | - | 6,522 | 6,522 | -% |
2023-09-20 | BARCLAYS PLC | added | 39.22 | 126,910,000 | 614,468,000 | 0.39% |
2023-09-14 | IMS Capital Management | added | 2.02 | -54,466 | 657,927 | 0.36% |
2023-09-13 | CGC Financial Services, LLC | new | - | 188,352 | 188,352 | 0.12% |
2023-09-12 | Farther Finance Advisors, LLC | added | 28.16 | 83,248 | 603,291 | 0.13% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 8.30% | 32,534,676 | SC 13G/A | |
Feb 03, 2023 | blackrock inc. | 7.9% | 30,790,122 | SC 13G/A | |
Feb 10, 2022 | vanguard group inc | 7.89% | 31,103,788 | SC 13G/A | |
Feb 01, 2022 | blackrock inc. | 7.9% | 30,982,611 | SC 13G | |
Feb 10, 2021 | vanguard group inc | 7.82% | 30,997,381 | SC 13G/A | |
Feb 01, 2021 | blackrock inc. | 7.4% | 29,504,221 | SC 13G/A | |
Feb 12, 2020 | vanguard group inc | 7.77% | 31,187,697 | SC 13G/A | |
Feb 06, 2020 | blackrock inc. | 7.0% | 28,202,856 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Sep 21, 2023 | 8-K/A | Current Report | |
Aug 31, 2023 | 4 | Insider Trading | |
Aug 30, 2023 | 144 | Notice of Insider Sale Intent | |
Aug 29, 2023 | 4 | Insider Trading | |
Aug 29, 2023 | 4 | Insider Trading | |
Aug 29, 2023 | 4 | Insider Trading | |
Aug 29, 2023 | 4 | Insider Trading | |
Aug 29, 2023 | 4 | Insider Trading | |
Aug 29, 2023 | 4 | Insider Trading | |
Aug 29, 2023 | 4 | Insider Trading |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
TMO | 191.4B | 43.5B | -11.02% | -2.25% | 33.42 | 4.4 | 1.64% | -23.14% |
MTD | 23.8B | 4.0B | -11.06% | 0.30% | 26.75 | 6.01 | 2.30% | 16.37% |
ILMN | 21.6B | 4.5B | -19.01% | -28.49% | -5.15 | 4.83 | -4.92% | -21931.58% |
WAT | 16.0B | 3.0B | -3.74% | 0.37% | 23.68 | 5.34 | 3.16% | -3.93% |
BRKR | 9.1B | 2.7B | -5.72% | 17.17% | 28.6 | 3.36 | 9.64% | 16.50% |
MID-CAP | ||||||||
NEO | 1.5B | 551.6M | -21.56% | 38.21% | -13.2 | 2.74 | 12.73% | 21.90% |
SMALL-CAP | ||||||||
PACB | 2.0B | 146.1M | -29.45% | 38.67% | -6.32 | 13.8 | 4.72% | -55.19% |
QTRX | 1.0B | 112.0M | -0.96% | 142.38% | -15.25 | 8.96 | 0.83% | 16.42% |
ADPT | 750.7M | 189.6M | -23.79% | -27.11% | -3.93 | 3.96 | 18.74% | 17.75% |
EYPT | 267.6M | 37.3M | -25.86% | -1.39% | -2.53 | 7.17 | -9.96% | -38.49% |
HBIO | 181.9M | 114.1M | -3.40% | 66.41% | -33.5 | 1.59 | -5.49% | -48.58% |
CDXS | 138.2M | 99.2M | 10.00% | -67.33% | -2.44 | 1.39 | -26.56% | -199.52% |
CDXC | 109.3M | 80.9M | -6.41% | 18.70% | -16.83 | 1.35 | 17.20% | 77.07% |
BNGO | 97.4M | 31.5M | -23.90% | 60.11% | -0.66 | 3.09 | 35.12% | -38.47% |
18.6%
17.9%
15.1%
4.5%
16.1%
0%
0%
Y-axis is the maximum loss one would have experienced if Thermo Fisher Scientific was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Revenue | -0.6% | 43,524 | 43,807 | 44,915 | 44,167 | 42,820 | 41,123 | 39,211 | 39,059 | 38,250 | 35,894 | 32,218 | 28,497 | 26,248 | 25,647 | 25,542 | 25,220 | 24,868 | 24,630 | 24,358 | 23,898 | 23,094 |
Costs and Expenses | 0.4% | 36,812 | 36,672 | 36,522 | 35,097 | 33,182 | 31,323 | 29,183 | 28,498 | 27,541 | 25,957 | 24,424 | 22,542 | 21,773 | 21,067 | 20,948 | 20,710 | 20,392 | 20,713 | 20,575 | 20,306 | 19,780 |
S&GA Expenses | -0.7% | 8,771 | 8,835 | 8,993 | 8,972 | 8,768 | 8,458 | 8,007 | 7,806 | 7,394 | 7,205 | 6,930 | 6,365 | 6,312 | 6,167 | 6,144 | 6,142 | 6,093 | 6,070 | 6,057 | 6,026 | 5,936 |
R&D Expenses | -1.4% | 1,433 | 1,453 | 1,471 | 1,472 | 1,472 | 1,450 | 1,406 | 1,390 | 1,335 | 1,256 | 1,181 | 1,067 | 1,018 | 1,000 | 1,003 | 992 | 985 | 981 | 967 | 949 | 926 |
EBITDA | -100.0% | - | 8,537 | 9,547 | 9,485 | 9,979 | 10,058 | 10,208 | 11,191 | 11,242 | 11,969 | 10,045 | 8,187 | 6,777 | 6,961 | 7,013 | 7,023 | 7,039 | 6,468 | 6,196 | 5,945 | 5,569 |
EBITDA Margin | -100.0% | - | 0.19* | 0.21* | 0.21* | 0.23* | 0.24* | 0.26* | 0.29* | 0.29* | 0.33* | 0.31* | 0.29* | 0.26* | 0.27* | 0.27* | 0.28* | 0.28* | 0.26* | 0.25* | 0.25* | 0.24* |
Interest Expenses | 20.0% | 1,068 | 890 | 726 | 618 | 573 | 547 | 536 | 521 | 537 | 552 | 553 | 549 | 569 | 613 | 676 | 712 | 740 | 756 | 667 | - | - |
Earnings Before Taxes | -7.3% | 6,171 | 6,658 | 7,835 | 7,920 | 8,496 | 8,628 | 8,841 | 9,876 | 9,951 | 9,155 | 7,230 | 5,373 | 3,943 | 4,083 | 4,072 | 4,044 | 4,032 | 3,445 | 3,262 | 3,070 | 2,740 |
EBT Margin | -100.0% | - | 0.15* | 0.17* | 0.18* | 0.20* | 0.21* | 0.23* | 0.25* | 0.26* | 0.25* | 0.22* | 0.19* | 0.15* | 0.16* | 0.16* | 0.16* | 0.16* | 0.14* | 0.13* | 0.13* | 0.12* |
Net Income | -5.1% | 5,726 | 6,032 | 6,960 | 7,045 | 7,450 | 7,611 | 7,728 | 8,569 | 8,599 | 7,926 | 6,377 | 4,879 | 3,706 | 3,669 | 3,696 | 3,592 | 3,541 | 3,174 | 2,938 | 2,568 | 2,393 |
Net Income Margin | -100.0% | - | 0.14* | 0.15* | 0.16* | 0.17* | 0.19* | 0.20* | 0.22* | 0.22* | 0.22* | 0.20* | 0.17* | 0.14* | 0.14* | 0.14* | 0.14* | 0.14* | 0.13* | 0.12* | 0.11* | 0.10* |
Free Cashflow | -100.0% | - | 5,620 | 6,911 | 5,600 | 6,336 | 7,001 | 6,789 | 7,916 | 8,132 | 8,062 | 6,815 | 5,686 | 4,245 | 3,702 | 4,047 | 3,940 | 4,086 | 4,273 | 3,785 | 3,919 | 3,690 |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Assets | -0.6% | 94,105 | 94,658 | 97,154 | 90,536 | 90,579 | 92,747 | 95,123 | 73,600 | 67,698 | 65,931 | 69,052 | 64,061 | 61,593 | 58,688 | 58,381 | 56,729 | 57,970 | 55,596 | 56,232 | 55,078 | 55,403 |
Current Assets | -1.1% | 19,995 | 20,209 | 25,229 | 19,299 | 18,100 | 18,776 | 20,113 | 24,724 | 19,260 | 17,685 | 21,957 | 18,234 | 15,775 | 12,738 | 11,893 | 10,514 | 11,223 | 9,939 | 10,625 | 9,566 | 9,474 |
Cash Equivalents | -10.0% | 3,133 | 3,482 | 8,524 | 2,919 | 1,905 | 2,779 | 4,491 | 12,048 | 7,035 | 5,603 | 10,336 | 7,570 | 5,837 | 3,010 | 2,422 | 1,305 | 2,314 | 1,128 | 2,117 | 1,111 | 956 |
Inventory | -0.2% | 5,655 | 5,664 | 5,634 | 5,722 | 5,668 | 5,483 | 5,051 | 4,906 | 4,625 | 4,342 | 4,029 | 3,829 | 3,648 | 3,454 | 3,370 | 3,308 | 3,209 | 3,124 | 3,005 | 2,982 | 2,866 |
Net PPE | -0.7% | 9,292 | 9,354 | 9,280 | 8,628 | 8,529 | 8,448 | 8,333 | 7,049 | 6,560 | 6,133 | 5,912 | 5,180 | 4,887 | 4,736 | 4,749 | 4,420 | 4,394 | 4,192 | 4,165 | 3,978 | 3,952 |
Goodwill | 0.3% | 43,273 | 43,140 | 41,196 | 40,488 | 41,066 | 41,721 | 41,924 | 26,909 | 26,904 | 26,823 | 26,041 | 25,782 | 25,700 | 25,614 | 25,714 | 25,624 | 25,757 | 25,236 | 25,347 | 25,142 | 25,120 |
Current Liabilities | -11.2% | 14,112 | 15,884 | 17,010 | 11,118 | 10,997 | 12,070 | 13,436 | 7,753 | 6,925 | 6,995 | 10,304 | 6,228 | 6,013 | 5,500 | 6,197 | 5,844 | 7,509 | 5,898 | 6,147 | 5,196 | 5,980 |
Long Term Debt | 0.2% | 29,194 | 29,135 | 28,909 | 28,150 | 29,250 | 31,389 | 32,333 | 21,688 | - | - | 19,107 | - | - | - | - | - | 16,663 | 16,812 | 17,719 | 17,760 | 17,709 |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | 18,773 | 18,641 | 19,107 | 21,091 | 20,638 | 19,231 | 17,076 | 16,392 | - | - | 17,719 | - | - |
Shareholder's Equity | 3.4% | 43,752 | 42,310 | 43,978 | 43,549 | 42,354 | 41,018 | 40,855 | 38,757 | 36,901 | 35,068 | 34,517 | 31,824 | 29,875 | 28,559 | 29,684 | 29,355 | 28,729 | 27,693 | 27,594 | 26,890 | 26,445 |
Retained Earnings | 2.8% | 44,289 | 43,064 | 41,910 | 40,452 | 39,074 | 37,528 | 35,431 | 33,876 | 32,076 | 30,350 | 28,116 | 25,705 | 23,860 | 22,791 | 22,092 | 21,165 | 20,482 | 19,439 | 18,700 | 17,866 | 17,226 |
Additional Paid-In Capital | 0.8% | 17,030 | 16,889 | 16,743 | 16,596 | 16,467 | 16,292 | 16,174 | 15,960 | 15,826 | 15,684 | 15,579 | 15,467 | 15,334 | 15,186 | 15,064 | 14,964 | 14,887 | 14,771 | 14,621 | 14,526 | 14,408 |
Shares Outstanding | 0% | 386 | 386 | - | 392 | 392 | 392 | - | 394 | 393 | 394 | - | 396 | 395 | 397 | - | 401 | 400 | 400 | - | 402 | 403 |
Minority Interest | -5.7% | 50.00 | 53.00 | 54.00 | 59.00 | 61.00 | 62.00 | 62.00 | - | - | - | 10.00 | - | - | - | - | - | - | - | - | - | - |
Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Cashflow From Operations | 0.2% | 7,693 | 7,681 | 9,154 | 8,124 | 8,837 | 9,536 | 9,312 | 10,194 | 10,252 | 9,911 | 8,289 | 6,863 | 5,272 | 4,680 | 4,973 | 4,861 | 4,964 | 5,114 | 4,543 | 4,608 | 4,317 |
Share Based Compensation | -1.0% | 302 | 305 | 307 | 309 | 283 | 257 | 230 | 204 | 205 | 201 | 196 | 188 | 178 | 183 | 181 | 182 | 186 | 182 | 181 | 180 | 179 |
Cashflow From Investing | -0.5% | -4,655 | -4,631 | -2,159 | -20,326 | -20,397 | -20,604 | -21,932 | -3,866 | -3,615 | -3,248 | -1,510 | -1,223 | -1,056 | -1,566 | -1,487 | -1,869 | -1,839 | -1,255 | -1,253 | -815 | -7,616 |
Cashflow From Financing | 19.9% | -1,809 | -2,258 | -2,810 | 3,266 | 6,457 | 8,286 | 6,581 | -1,935 | -5,766 | -4,510 | 959 | 494 | -584 | -1,074 | -3,118 | -2,617 | -1,624 | -3,320 | -2,237 | -3,368 | 3,589 |
Dividend Payments | 3.8% | 487 | 469 | 455 | 441 | 425 | 411 | 395 | 379 | 364 | 348 | 337 | 326 | 316 | 305 | 297 | 289 | 281 | 274 | 266 | 258 | 248 |
Buy Backs | 0% | 4,000 | 4,000 | 3,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 1,500 | 2,250 | 2,250 | 2,250 | 1,500 | 1,000 | 1,250 | 1,250 | 500 | 250 | - |
Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jul. 01, 2023 | Jul. 02, 2022 | Jul. 01, 2023 | Jul. 02, 2022 | |
Revenues | ||||
Revenues | $ 10,687 | $ 10,970 | $ 21,397 | $ 22,788 |
Costs and operating expenses: | ||||
Selling, general and administrative expenses | 2,145 | 2,209 | 4,264 | 4,486 |
Research and development expenses | 345 | 365 | 691 | 729 |
Restructuring and other costs | 183 | 24 | 295 | 26 |
Total costs and operating expenses | 9,109 | 8,969 | 18,256 | 17,966 |
Operating income | 1,578 | 2,001 | 3,141 | 4,822 |
Interest income | 178 | 36 | 324 | 54 |
Interest expense | (326) | (148) | (626) | (284) |
Other income/(expense) | 0 | 28 | (46) | (135) |
Income before income taxes | 1,430 | 1,917 | 2,793 | 4,457 |
Provision for income taxes | (52) | (198) | (98) | (499) |
Equity in earnings/(losses) of unconsolidated entities | (16) | (51) | (41) | (70) |
Net income | 1,362 | 1,668 | 2,654 | 3,888 |
Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest | 1 | 4 | 4 | 9 |
Net income attributable to Thermo Fisher Scientific Inc. | $ 1,361 | $ 1,664 | $ 2,650 | $ 3,879 |
Earnings per share attributable to Thermo Fisher Scientific Inc. | ||||
Basic (in dollars per share) | $ 3.53 | $ 4.25 | $ 6.86 | $ 9.90 |
Diluted (in dollars per share) | $ 3.51 | $ 4.22 | $ 6.83 | $ 9.83 |
Weighted average shares | ||||
Basic (in shares) | 386 | 392 | 386 | 392 |
Diluted (in shares) | 388 | 394 | 388 | 394 |
Product revenues | ||||
Revenues | ||||
Revenues | $ 6,271 | $ 7,003 | $ 12,675 | $ 15,020 |
Costs and operating expenses: | ||||
Cost of revenues | 3,278 | 3,516 | 6,615 | 7,071 |
Service revenues | ||||
Revenues | ||||
Revenues | 4,416 | 3,967 | 8,722 | 7,768 |
Costs and operating expenses: | ||||
Cost of revenues | $ 3,158 | $ 2,855 | $ 6,391 | $ 5,654 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions | Jul. 01, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 3,133 | $ 8,524 |
Accounts receivable, less allowances of $180 and $189 | 8,019 | 8,115 |
Inventories | 5,655 | 5,634 |
Contract assets, net | 1,467 | 1,312 |
Other current assets | 1,721 | 1,644 |
Total current assets | 19,995 | 25,229 |
Property, plant and equipment, net | 9,292 | 9,280 |
Acquisition-related intangible assets, net | 17,437 | 17,442 |
Other assets | 4,108 | 4,007 |
Goodwill | 43,273 | 41,196 |
Total assets | 94,105 | 97,154 |
Current liabilities: | ||
Short-term obligations and current maturities of long-term obligations | 4,814 | 5,579 |
Accounts payable | 2,423 | 3,381 |
Accrued payroll and employee benefits | 1,310 | 2,095 |
Contract liabilities | 2,590 | 2,601 |
Other accrued expenses | 2,975 | 3,354 |
Total current liabilities | 14,112 | 17,010 |
Deferred income taxes | 2,842 | 2,849 |
Other long-term liabilities | 4,042 | 4,238 |
Long-term obligations | 29,194 | 28,909 |
Redeemable noncontrolling interest | 113 | 116 |
Thermo Fisher Scientific Inc. shareholders’ equity: | ||
Preferred stock, $100 par value, 50,000 shares authorized; none issued | 0 | 0 |
Common stock, $1 par value, 1,200,000,000 shares authorized; 441,398,059 and 440,668,112 shares issued | 441 | 441 |
Capital in excess of par value | 17,030 | 16,743 |
Retained earnings | 44,289 | 41,910 |
Treasury stock at cost, 55,448,286 and 50,157,275 shares | (15,084) | (12,017) |
Accumulated other comprehensive income/(loss) | (2,924) | (3,099) |
Total Thermo Fisher Scientific Inc. shareholders’ equity | 43,752 | 43,978 |
Noncontrolling interests | 50 | 54 |
Total equity | 43,802 | 44,032 |
Total liabilities, redeemable noncontrolling interest and equity | $ 94,105 | $ 97,154 |